99mtc-mibi scintigraphy in untreated stage iii multiple myeloma: comparison with x-ray skeletal survey and bone scintigraphy

Nuclear Medicine Communications

Volumn 24, Issue 5, 2003, Pages 537-542

  Alper, E ^a   Gurel, M ^a   Evrensel, T ^a   Ozkocaman, V ^a   Akbunar, T ^a   Demİray, M ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

99mTc MIBI; Bone scintigraphy; Multiple myeloma

Indexed keywords

DIAGNOSTIC AGENT; MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW CANCER; BONE TUMOR; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; WHOLE BODY COUNTING;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW NEOPLASMS; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TECHNETIUM TC 99M SESTAMIBI; WHOLE-BODY COUNTING;

EID: 0346225572     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200305000-00009     Document Type: Article

References (21)

1. Barlogie B. Plasma cell myeloma. In: Bentler E, Marshall AL, eds. Williams hematology. New York: McGraw Hill, 1995: 1109-1126.
2. Woolfenden JM, Pitt MJ, Durie BG, Moon TE. Comparison of bone scintigraphy and radiography in myeloma. Radiology 1980; 134: 723-727.
3. Ludwig H, Kumpan W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol 1982; 55: 173-181.
4. Scutellari PN, Spanedda R, Feggi LM, Cervi PM. The value and limitations of total body scan in the diagnosis of multiple myeloma: a comparison with conventional skeletal radiography. Haematologica 1985; 70: 136-142.
5. Olson P, Everson LI, Griffiths HJ. Staging of musculoskeletal tumors. Radiol Clin N Am 1994; 32: 151-162.
6. El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m MIBI versus fluorine-18 FDG in diffuse multiple myeloma. J Nucl Med 1997; 38: 1208-1210.
7. Durie BGM, Waxman A, Jochelson M, Giles FJ, Hamburg S, Avedon M. Technetium-99m-MIBI scanning in multiple myeloma. Proc Am Soc Clin Oncol 1994; 13: 411.
8. Tirovola EB, Biassoni L, Britton KE, Kaleva N, Kouykin V, Malpas JS. The use of Tc-99m-MIBI scanning in multiple myeloma. Br J Cancer 1996; 74: 1815-1820.
9. Adams BK, Fataar A, Nizami MA. Technetium-99m-sestamibi uptake in myeloma. J Nucl Med 1996; 37: 1001-1002.
10. Pace L, Catalano L, Pinto A, et al. Different patterns of Tc-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998; 25: 714-720.
11. Catalano L, Pace L, Califano C, et al. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 1999; 84: 119-124.
12. Durie BGM, Waxman AD, D'Agnolo A, Williams CM. Whole body Tc-99m MIBI scanning in the serial evaluation of multiple myeloma: comparison with other techniques including whole body FDG. J Nucl Med 1999; 40: 215.
13. Fonti R, Del Vecchio S, Zannetti A, et al. Bone marrow uptake of Tc-99m MIBI in patients with multiple myeloma. Eur J Nucl Med 2001; 28: 214-220.
14. Watanabe N, Shimizu M, Kageyama M, et al. Multiple myeloma evaluated with Tl-201 scintigraphy compared with bone scintigraphy. J Nucl Med 1999; 40: 1138-1142.
15. Alexandrakis MG, Kyriakou DS, Passam F, Koukouraki S, Karkavitsas N. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Ann Hematol 2001; 80: 349-353.
16. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-854.
17. Feggi LM, Spanedda R, Scutellari PN, Prandini N, Gennari M, Orzincolo C. Bone marrow scintigraphy in multiple myeloma: a comparison with bone scintigraphy skeletal radiology. Radiologica Medica 1988; 76: 311-315.
18. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
19. Del Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
20. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
21. Wakasugi S, Teshima H, Nakamura H, et al. Tc-99m MIBI localization in bone marrow: a marker of bone marrow malignancy. Clin Nucl Med 1998; 23: 664-671.